

**REMARKS**

In the instant Office Action, the Examiner has required restriction of the claimed invention, and listed the following group classifications:

<b>Group</b>	<b>Claims</b>	<b>Description</b>
I	1-12 & 26-32	methods for detecting AC7 polymorphisms
II	13-18 (19)	kits for detecting AC7 polymorphisms
III	21 (20, 24, 25)	methods for screening compounds that alter AC7 mRNA
IV	22 (20, 24, 25)	methods for screening compounds that alter AC7 protein
V	23 (20, 24, 25)	methods for screening compounds that alter AC7 activity

Applicants hereby elect to prosecute Claims 1-12 and 26-32 of Group I, without traverse. Moreover Applicants request consideration of the references listed on the Information Disclosure Statement enclosed herein, before the mailing of a first substantive Office Action. However, should the Examiner believe that a telephone interview would aid in the prosecution of this application, Applicants encourage the Examiner to call the undersigned collect.

Dated: July 20, 2006



Christine A. Lekutis  
Registration No. 51,934

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415/904-6500